|
Press Releases |
|
 |
|
Wednesday, September 5, 2018 |
|
NANOBIOTIX half year results for the six months ended June 30, 2018 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018. more info >> |
|
Friday, July 27, 2018 |
|
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. more info >> |
|
Friday, June 22, 2018 |
|
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS). more info >> |
|
Wednesday, June 6, 2018 |
|
NANOBIOTIX' Management Statement on Recent Share Price Variation |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. more info >> |
|
Friday, May 4, 2018 |
|
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action. more info >> |
|
Wednesday, April 18, 2018 |
|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018). more info >> |
|
Wednesday, April 11, 2018 |
|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product. more info >> |
|
Friday, March 30, 2018 |
|
Nanobiotix 2017 Annual Results |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017. more info >> |
|
Monday, January 22, 2018 |
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors. more info >> |
|
Thursday, January 11, 2018 |
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Buy International Homes at the Global Property Expo, Singapore
Jul 15, 2025 20:06 HKT/SGT
|
|
|
XDS Datacentres signs 15-year deal to host 10MW of AI workloads in Saudi's Desert Dragons facilities
Jul 15, 2025 19:41 HKT/SGT
|
|
|
U.S. Polo Assn. Celebrates Seventh Year Supporting the 2025 Outsourcing Inc. Royal Charity Polo Cup
Jul 15, 2025 19:00 HKT/SGT
|
|
|
Ocean One Seizing Business Opportunities with Main Board Listing Application
Jul 15, 2025 19:00 HKT/SGT
|
|
|
大洋環球申轉主板上市捉緊商機 迎中國恢復部分日本水產進口機遇
Jul 15, 2025 18:22 HKT/SGT
|
|
|
大洋环球申转主板上市捉紧商机 迎中国恢复部分日本水产进口机遇
Jul 15, 2025 18:10 HKT/SGT
|
|
|
雲頂新耀股價創階段新高 通用型現貨腫瘤治療性疫苗EVM14「中美雙報」再釋mRNA平台潛力
Jul 15, 2025 17:40 HKT/SGT
|
|
|
云顶新耀股价创阶段新高 通用型现货肿瘤治疗性疫苗EVM14"中美双报"再释mRNA平台潜力
Jul 15, 2025 17:34 HKT/SGT
|
|
|
耀啟新程!康哲藥業今日於新加坡交易所主板實現二次上市
Jul 15, 2025 17:05 HKT/SGT
|
|
|
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
Jul 15, 2025 17:00: JST
|
|
|
耀启新程!康哲药业今日于新加坡交易所主板实现二次上市
Jul 15, 2025 16:53 HKT/SGT
|
|
|
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
Jul 15, 2025 16:00 HKT/SGT
|
|
|
ONERHT Foundation Announces 8th edition of GAIL Forum which will focus on Green Leadership in ASEAN
Jul 15, 2025 13:00 HKT/SGT
|
|
|
PCG Collaborates with Big Boss Taxi and STAY BAR to Usher in a Cashless Era
Jul 15, 2025 12:30 HKT/SGT
|
|
|
交易寶攜手Big Boss Taxi與STAY BAR開啟無現金新時代
Jul 15, 2025 12:30 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|